GLP-1 Drugs and Their Popularity Among Seniors
GLP-1 medications have emerged as a leading option in the weight management arena this year, yet certain elderly individuals in America are choosing to abandon this trend.
Research released in JAMA during January 2025, examining over 125,000 individuals who are overweight or obese, indicated that approximately 47% of participants with type 2 diabetes and 65% without diabetes discontinued their GLP-1 prescriptions within twelve months of initiation.
Dr. John Batsis, an expert in geriatrics and obesity at the University of North Carolina School of Medicine, shared with The New York Times in a recent article that adults aged 65 and above represent "ideal candidates" for these medications, given that obesity affects roughly 40% of older people.
Understanding GLP-1 Medications
These pharmaceuticals replicate a hormone in the gut known as glucagon-like peptide-1, primarily prescribed for managing type 2 diabetes and controlling weight. Additionally, they undergo trials for addressing various other health issues, including sleep apnea and heart-related events.
Initiating and then halting these drugs frequently results in regained weight, heightened hunger, and forfeiture of related benefits such as lower blood pressure and cholesterol, as noted by Stamford Health and specialists. The likelihood of conditions tied to obesity, like heart problems and sleep apnea, may also rise.
Reasons for Discontinuation Among Older Adults
Regardless of the potential drawbacks, elderly Americans are reportedly forsaking their weight-loss drugs for several motives, ranging from severe adverse reactions to escalating expenses.
The subsequent section outlines the primary four factors that might lead seniors to abandon their GLP-1 treatments.
Financial Challenges and Accessibility Issues
The cost of GLP-1 medications poses a significant hurdle in maintaining therapy, particularly amid shortages that limit supply.
The New York Times recounted the experience of Mary Bucklew, a 75-year-old retired transit worker from Delaware, who initially paid only $25 monthly through her insurance for Ozempic to manage weight.
After shedding 25 pounds over six months and reporting boosted vitality, Bucklew received notice from her insurer that coverage for the medication would end, despite her pleas regarding its health necessity.
Without insurance support, the prescription would exceed $1,000 monthly out-of-pocket, forcing her to cease usage, as detailed in the report.
Certain GLP-1 producers have taken steps to enhance affordability. In December 2025, Lilly declared a reduction in the price of Zepbound (tirzepatide) single-dose vials.
"An excessive number of individuals requiring obesity therapies encounter obstacles related to expenses and coverage," stated Ilya Yuffa, executive vice president and head of Lilly USA, in the press release. "This measure highlights Lilly's dedication to enhancing availability in obesity care. We remain committed to offering additional alternatives, such as varied delivery methods and novel access routes, enabling more patients to obtain essential treatments."
Common Side Effects
In a conversation with Fox News Digital, Dr. Sue Decotiis, a physician specializing in medical weight reduction in New York City, affirmed that over half of elderly patients halt GLP-1 usage because of expenses or unwanted effects.
Frequent adverse reactions encompass nausea, vomiting, diarrhea, constipation, bloating, headaches, tiredness, and hair loss, as per specialists.
